JPS6244504B2 - - Google Patents
Info
- Publication number
- JPS6244504B2 JPS6244504B2 JP50127285A JP12728575A JPS6244504B2 JP S6244504 B2 JPS6244504 B2 JP S6244504B2 JP 50127285 A JP50127285 A JP 50127285A JP 12728575 A JP12728575 A JP 12728575A JP S6244504 B2 JPS6244504 B2 JP S6244504B2
- Authority
- JP
- Japan
- Prior art keywords
- drug
- housing
- powered
- implanted
- power source
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003814 drug Substances 0.000 claims description 153
- 229940079593 drug Drugs 0.000 claims description 148
- 238000011156 evaluation Methods 0.000 claims description 12
- 238000011157 data evaluation Methods 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 230000009471 action Effects 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 3
- 238000004377 microelectronic Methods 0.000 claims 6
- 230000004962 physiological condition Effects 0.000 claims 1
- 230000035790 physiological processes and functions Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 description 29
- 238000000718 qrs complex Methods 0.000 description 24
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 22
- 239000000126 substance Substances 0.000 description 21
- 230000036772 blood pressure Effects 0.000 description 19
- 238000000034 method Methods 0.000 description 19
- 238000012377 drug delivery Methods 0.000 description 18
- 210000002216 heart Anatomy 0.000 description 17
- 238000010586 diagram Methods 0.000 description 16
- 230000007246 mechanism Effects 0.000 description 14
- 230000000747 cardiac effect Effects 0.000 description 12
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 238000012544 monitoring process Methods 0.000 description 11
- 229960001404 quinidine Drugs 0.000 description 11
- 230000000737 periodic effect Effects 0.000 description 8
- 208000003734 Supraventricular Tachycardia Diseases 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 230000002889 sympathetic effect Effects 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000003098 Ganglion Cysts Diseases 0.000 description 4
- 208000005400 Synovial Cyst Diseases 0.000 description 4
- 239000002220 antihypertensive agent Substances 0.000 description 4
- 206010003119 arrhythmia Diseases 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003457 ganglion blocking agent Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 201000005857 malignant hypertension Diseases 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 229940127088 antihypertensive drug Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- -1 polysiloxane Polymers 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000001326 carotid sinus Anatomy 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000002565 electrocardiography Methods 0.000 description 2
- 238000000537 electroencephalography Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003509 long acting drug Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000000661 pacemaking effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 229920002379 silicone rubber Polymers 0.000 description 2
- 239000004945 silicone rubber Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000000331 sympathetic ganglia Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 208000003663 ventricular fibrillation Diseases 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010003662 Atrial flutter Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000005633 Chrysanthemum balsamita Nutrition 0.000 description 1
- 244000260524 Chrysanthemum balsamita Species 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- VZJFGSRCJCXDSG-UHFFFAOYSA-N Hexamethonium Chemical compound C[N+](C)(C)CCCCCC[N+](C)(C)C VZJFGSRCJCXDSG-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 208000012826 adjustment disease Diseases 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- GZCGUPFRVQAUEE-VANKVMQKSA-N aldehydo-L-glucose Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-VANKVMQKSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 210000002413 aortic body Anatomy 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960004980 betanidine Drugs 0.000 description 1
- NIVZHWNOUVJHKV-UHFFFAOYSA-N bethanidine Chemical compound CN\C(=N/C)NCC1=CC=CC=C1 NIVZHWNOUVJHKV-UHFFFAOYSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- AAQOQKQBGPPFNS-UHFFFAOYSA-N bretylium Chemical compound CC[N+](C)(C)CC1=CC=CC=C1Br AAQOQKQBGPPFNS-UHFFFAOYSA-N 0.000 description 1
- 229960002624 bretylium tosilate Drugs 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000002371 cardiac agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011982 device technology Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000013266 extended drug release Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- ANSXAPJVJOKRDJ-UHFFFAOYSA-N furo[3,4-f][2]benzofuran-1,3,5,7-tetrone Chemical compound C1=C2C(=O)OC(=O)C2=CC2=C1C(=O)OC2=O ANSXAPJVJOKRDJ-UHFFFAOYSA-N 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229960003602 guanethidine Drugs 0.000 description 1
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical group NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 229950002932 hexamethonium Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 210000000192 parasympathetic ganglia Anatomy 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 210000004203 pyloric antrum Anatomy 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000000954 sacrococcygeal region Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000003421 short acting drug Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Electrotherapy Devices (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP50127285A JPS5254280A (en) | 1975-10-22 | 1975-10-22 | Builttin selffdrive device for administering medicine with timing and evaluating units and method therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP50127285A JPS5254280A (en) | 1975-10-22 | 1975-10-22 | Builttin selffdrive device for administering medicine with timing and evaluating units and method therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5254280A JPS5254280A (en) | 1977-05-02 |
| JPS6244504B2 true JPS6244504B2 (fr) | 1987-09-21 |
Family
ID=14956179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50127285A Granted JPS5254280A (en) | 1975-10-22 | 1975-10-22 | Builttin selffdrive device for administering medicine with timing and evaluating units and method therefor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5254280A (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4308866A (en) * | 1978-11-02 | 1982-01-05 | University Of Southern California | Infusion controlling apparatus and method |
| US4619653A (en) * | 1979-04-27 | 1986-10-28 | The Johns Hopkins University | Apparatus for detecting at least one predetermined condition and providing an informational signal in response thereto in a medication infusion system |
| JPS56151052A (en) * | 1980-04-02 | 1981-11-21 | Medtronic Inc | Dosage device |
| US4596558A (en) * | 1985-09-13 | 1986-06-24 | Queen's University At Kingston | Pulsed external medication dispenser |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS50131393A (fr) * | 1974-03-30 | 1975-10-17 |
-
1975
- 1975-10-22 JP JP50127285A patent/JPS5254280A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS50131393A (fr) * | 1974-03-30 | 1975-10-17 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5254280A (en) | 1977-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4003379A (en) | Apparatus and method for implanted self-powered medication dispensing | |
| US3923060A (en) | Apparatus and method for implanted self-powered medication dispensing having timing and evaluator means | |
| US7481759B2 (en) | Systems and methods for treatment of coronary artery disease | |
| US8934968B2 (en) | Neurostimulation and coronary artery disease treatment | |
| EP1385570B1 (fr) | Appareil medical implantable et systeme de timbre | |
| US20070083240A1 (en) | Methods and systems for applying stimulation and sensing one or more indicators of cardiac activity with an implantable stimulator | |
| US6453195B1 (en) | Closed loop drug delivery system and remote management thereof | |
| EP1624929B1 (fr) | Appareil de surveillance d'oedeme pulmonaire | |
| EP2166942B1 (fr) | Système de titration en thérapie décongestive pour des patients atteints d'insuffisance cardiaque en utilisant un capteur implantable | |
| US20040106954A1 (en) | Treatment of congestive heart failure | |
| US20040162590A1 (en) | Fully implantable miniature neurostimulator for intercostal nerve stimulation as a therapy for angina pectoris | |
| US7722598B2 (en) | Apparatus and system for delivery of drug therapies | |
| US8515541B1 (en) | Methods and systems for treating post-stroke disorders | |
| WO2008083235A2 (fr) | Formes d'onde de stimulation pour activation du baroréflexe | |
| WO2002087693A9 (fr) | Stimulation cardiaque asservie en frequence, en fonction de la pression | |
| JP2008521566A (ja) | 心膜空間内に治療を提供する方法及びシステム | |
| JP2010527257A (ja) | 血液量調整のための刺激システム | |
| WO2000074773A1 (fr) | Dispositif d'administration de medicaments | |
| US8046064B2 (en) | Method of delivering PESP/ICC as well as adjusting the refractory period of the heart | |
| JPS6244504B2 (fr) | ||
| EP2201980A1 (fr) | Stimulateur implantable | |
| Zecchi et al. | Clinical benefit of closed loop stimulation-Preliminary results of an intensive validation study | |
| JP2002515766A (ja) | 埋め込み型薬理学的除細動器システム | |
| Chapman | Implantable Cardioverter-Defibrillators | |
| WO1997004834A2 (fr) | Systeme de defibrillateur pharmacologique implantable |